CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
Renier Brentjens, MD, PhD, one of the pioneers in the development of chimeric antigen receptor (CAR) T-cell therapy, is poised to see the technology take its next big leap, with researchers testing ...
Revealing a biological combat strategy worthy of a five-star general, researchers from Houston Methodist Hospital, University of Chicago and Cornell University have shown how a cell surface ...
CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...
Scientists have discovered that T cell receptors activate through a hidden spring-like motion that had never been seen before. This breakthrough may help explain why immunotherapy works for some ...
CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has revolutionized how physicians treat cancer, especially blood cancers. “These patients can be cured ...
T cells are essential components of the immune system and play critical roles in immune responses against infections, tumors, and autoimmune diseases. T cells are highly heterogeneous, with distinct ...
A substantial proportion of patients with autoimmune diseases experienced a new side effect called local immune effector cell–associated toxicity syndromes (LICATS) after receiving chimeric antigen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results